Improving Access to Trikafta for Cystic Fibrosis Patients in South Africa

By João L. Carapinha

December 16, 2024

The Competition Commission of South Africa recently published a media statement on cystic fibrosis medication access – Trikafta. This article highlights improvements in access to Trikafta, a critical medication for cystic fibrosis patients. Access to Trikafta has been primarily enhanced through the mechanisms established by Vertex Pharmaceuticals which has passed a review by the Competition Commission of South Africa.

Section 21 of the Medicines and Related Substances Act

– Section 21 allows SAHPRA to authorize the sale of unregistered medicines in South Africa under certain conditions. This provision enables registered medical practitioners to apply for approval to use unregistered medicines, such as Trikafta, for individual patients.
– In the context of Trikafta, Vertex has committed to making this medication available through Section 21. This approach allows patients in South Africa to access Trikafta even if it is not fully registered with SAHPRA.

Patient Access Program and Financial Assistance

– Vertex launched a patient assistance program, managed by an NGO, to reduce financial burdens on eligible patients. This initiative ensures that some cystic fibrosis patients can access Trikafta at no cost.
– Eligible patients under specific medical schemes can access Trikafta for free through financial assistance. This includes support from top-end medical plans offered by Discovery Health.

Impact on Access to Medicine Initiatives

– The decision by the Competition Commission to accept Vertex’s undertakings and non-refer the complaint is viewed as a positive outcome for access to medicine initiatives in South Africa. It guarantees that patients can access life-changing medications like Trikafta locally, at a more affordable price than before.
– The local distribution of Trikafta, starting in April 2024, significantly enhances the medication’s accessibility. Patients will no longer have to import it from other countries, aligning with public interest and the objectives of the Competition Act.

Conclusion

Overall, the initiatives undertaken by Vertex, reviewed by the Competition Commission, represent a marked improvement in access to Trikafta for cystic fibrosis patients in South Africa. The implementation of Section 21 authorizations and patient assistance programs makes this critical medication more accessible and affordable, which is a positive advancement for access to medicine initiatives in the country.

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.